Bevacizumab increased T cell and B cell compartments in patients with metastatic colorectal cancer [19], improved the cytotoxic T lymphocytes response in patients with metastatic non-small-cell lung cancer [20], expanded the extent of CD3+ and CD8+ T cell infiltration in glioblastoma tissues of patients [21] and sustained the circulation of the effector T cells in patients with ovarian cancer [22]. The gene discussed is CD8A; the disease is metastatic colorectal cancer.